Literature DB >> 31841874

Prevalence of DSM-5 somatic symptom disorder in Chinese outpatients from general hospital care.

Jinya Cao1, Jing Wei2, Kurt Fritzsche3, Anne Christin Toussaint4, Tao Li1, Yinan Jiang1, Lan Zhang5, Yaoyin Zhang6, Hua Chen7, Heng Wu8, Xiquan Ma9, Wentian Li10, Jie Ren11, Wei Lu12, Anne-Maria Müller3, Rainer Leonhart13.   

Abstract

OBJECTIVE: We aimed to explore the prevalence of somatic symptom disorder (SSD) according to DSM-5 criteria in Chinese outpatients from general hospital departments.
METHODS: This multicentre cross-sectional study enrolled 699 patients from outpatient departments, including the neurology, gastroenterology, Traditional Chinese Medicine [TCM] and psychosomatic medicine departments, in five cities in China. The structured clinical interview for DSM-5 (SCID-5) for SSD was administered by trained clinical professionals to diagnose SSD.
RESULTS: SSD was diagnosed in 33.8% (236/697) of all enrolled patients. The prevalence of SSD differed significantly among the departments (χ2 = 34.049, df = 2, p ≤0.001). No differences were found between SSD patients and non-SSD patients in terms of gender, residence, marital and living statuses, family income, education, employment status and lifestyle factors. However, patients with SSD reported higher levels of depression, health-related and general anxiety, lower physical and mental quality of life, higher frequency of doctor visits, increased time devoted to physical symptoms and longer duration of somatic symptoms. In a binary linear regression analysis, SSD was significantly associated with an increase in health-related anxiety, time devoted to symptoms and impact of somatic symptoms on daily life. The explained variance was Nagelkerke R2 = 0.45.
CONCLUSION: There is a high prevalence of SSD in Chinese general hospital outpatient clinics. The diagnosis is associated with high levels of emotional distress and low quality of life. There is a danger of over-diagnosis if we include the mild and moderate forms of SSD. Future studies are warranted to investigate the prevalence of SSD in inpatient departments and the development of psychological interventions for these patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  China; DSM-5; Prevalence; Somatic symptom disorder

Year:  2019        PMID: 31841874     DOI: 10.1016/j.genhosppsych.2019.11.010

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  5 in total

Review 1.  Somatic symptom disorder: a scoping review on the empirical evidence of a new diagnosis.

Authors:  Bernd Löwe; James Levenson; Miriam Depping; Paul Hüsing; Sebastian Kohlmann; Marco Lehmann; Meike Shedden-Mora; Anne Toussaint; Natalie Uhlenbusch; Angelika Weigel
Journal:  Psychol Med       Date:  2021-11-15       Impact factor: 7.723

2.  Gender differences in psychiatric outpatients: a before and during COVID-19 pandemic study in general hospitals from China.

Authors:  Wenli He; Danhong Xu; Jiafeng Wang; Yuze Shen; Zheng Lin; Liemin Ruan; Qiaozhen Chen
Journal:  Ann Gen Psychiatry       Date:  2022-09-07       Impact factor: 3.301

3.  Ethnic and migration-related inequalities in health anxiety: A systematic review and meta-analysis.

Authors:  Rieke Barbek; Sinje Henning; Julia Ludwig; Olaf von dem Knesebeck
Journal:  Front Psychol       Date:  2022-08-26

4.  Gender Differences in Disease, Function, and Behavioral Symptoms in Residents with Dementia.

Authors:  Barbara Resnick; Elizabeth Galik; Rachel McPherson; Marie Boltz; Kimberly Van Haitsma; Ann Kolanowski
Journal:  West J Nurs Res       Date:  2021-05-28       Impact factor: 1.774

5.  Assessment of the structured clinical interview (SCID) for DSM-5 for somatic symptom disorder in general hospital outpatient clinics in China.

Authors:  Yinan Jiang; Jing Wei; Kurt Fritzsche; Anne Christin Toussaint; Tao Li; Jinya Cao; Lan Zhang; Yaoyin Zhang; Hua Chen; Heng Wu; Xiquan Ma; Wentian Li; Jie Ren; Wei Lu; Rainer Leonhart
Journal:  BMC Psychiatry       Date:  2021-03-10       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.